Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark:The SHADE by Thorsteinsson, Kristina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Persistence of cervical high-risk human papillomavirus in women living with HIV in
Denmark
Thorsteinsson, Kristina; Ladelund, Steen; Storgaard, Merete; Katzenstein, Terese L.;
Johansen, Isik Somuncu; Pedersen, Gitte; Rönsholt, Frederikke Falkencrone; Nielsen, Lars
Nørregård; Nilas, Lisbeth; Franzmann, Maria; Obel, Niels; Lebech, Anne Mette; Bonde,
Jesper
Published in:
BMC Infectious Diseases
DOI:
10.1186/s12879-019-4377-5
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Thorsteinsson, K., Ladelund, S., Storgaard, M., Katzenstein, T. L., Johansen, I. S., Pedersen, G., ... Bonde, J.
(2019). Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark: The
SHADE. BMC Infectious Diseases, 19, [740]. https://doi.org/10.1186/s12879-019-4377-5
Download date: 04. Feb. 2020
RESEARCH ARTICLE Open Access
Persistence of cervical high-risk human
papillomavirus in women living with HIV in
Denmark – the SHADE
Kristina Thorsteinsson1* , Steen Ladelund2, Merete Storgaard3, Terese L. Katzenstein4,5, Isik Somuncu Johansen6,
Gitte Pedersen7, Frederikke Falkencrone Rönsholt4, Lars Nørregård Nielsen8, Lisbeth Nilas5,9, Maria Franzmann10,
Niels Obel4,5, Anne-Mette Lebech1,4 and Jesper Bonde10
Abstract
Background: Women living with HIV (WLWH) have high rates of persistent high-risk human papillomavirus (hrHPV)
infections and cervical cancer. We aimed to assess the distribution of hrHPV genotypes, risk factors of type-specific
hrHPV persistence, and high-grade squamous intraepithelial lesions or worse (≥HSIL) in WLWH in Denmark.
Methods: From the prospective Study on HIV, cervical Abnormalities and infections in women in Denmark (SHADE)
we identified WLWH with a positive hrHPV test during the study period; 2011–2014. HIV demographics were
retrieved from the Danish HIV Cohort Study and pathology results from the The Danish Pathology Data Bank.
Logistic regression was used to identify risk factors associated with persistent hrHPV infection (positivity of the same
hrHPV type in two samples one-two years after the first hrHPV positive date) and ≥ HSIL.
Results: Of 71 WLWH, 31 (43.7%) had persistent hrHPV infection. Predominant hrHPV genotypes were HPV58, 52,
51, and 35 and most frequently observed persistent genotypes were HPV52, 33 and 31. CD4 < 350 cells/μL
predicted genotype-specific hrHPV persistence (adjusted OR 4.36 (95%CI: 1.18–16.04)) and ≥ HSIL was predicted by
prior AIDS (adjusted OR 8.55 (95% CI 1.21–60.28)).
Conclusions: This prospective cohort study of well-treated WLWH in Denmark found a high rate of persistent hrHPV
infections with predominantly non-16/18 hrHPV genotypes. CD4 count < 350 cells/μL predicted hrHPV persistence,
while prior AIDS predicted ≥HSIL.
Keywords: Women living with HIV, Immunodeficiency, HPV persistence, High-risk HPV, HPV genotype distribution,
Cervical cancer
Highlights
Persistent hrHPV infection with non-16/18 was highly
prevalent in women living with HIV.
Multiple hrHPV infections was seen in a third of
participating women living with HIV.
Low CD4 count predicted hrHPV persistence.
Cytological abnormalities were predicted by short
duration of ART and prior AIDS.
Background
Persistent infection with high-risk human papillomavirus
(hrHPV) is a prerequisite for the development of cervical
cancer (CC) [1]. Yet, the majority of acquired HPV in-
fections are transient and naturally cleared by the
immune system within a few months [1]. HrHPV geno-
types differ in their carcinogenic potential and therefore
genotype distribution has an impact on the risk of CC
development [1–5].
Two modalities are available to prevent CC; primary
prevention through vaccine, and secondary prevention
through screening with cytology and hrHPV testing. As
current vaccines do not cover all oncogenic HPV geno-
types, nor eliminate existing infections at time of
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vaccination [6], screening remains an important prevent-
ive effort. In the general population, the impact of cer-
vical screening on CC mortality is well described [7].
However, the inability of current screening technologies
to distinguish between transient and persistent HPV in-
fection is an important cause of overtreatment [8].
Women living with HIV (WLWH) have a higher
prevalence of hrHPV, a higher rate of persistent hrHPV
infection, and a higher rate of cervical intraepithelial
neoplasia (CIN) and CC compared to HIV-negative
women [1, 4, 9–12]. Moreover, the hrHPV genotype dis-
tribution differs between the two populations [13–16].
With the longevity gained from combined antiretro-
viral therapy (ART) [17, 18] the burden of HPV-related
cancer is of increasing concern in people living with
HIV (PLWH) [17]. Moreover, the impact of ART on
hrHPV and cervical lesions are still debatable [9]. As pri-
mary prevention, European HIV guidelines recommend
HPV vaccination of WLWH through age 26 [19]. As
secondary prevention, HPV based screening is currently
substituting cytology screening in many European coun-
tries. Yet, the high hrHPV prevalence amongst WLWH
challenges HPV based screening as this results in lower
specificity compared to cervical cytology screening [20].
The ideal way to adopt screening programs for WLWH
is therefore still unresolved.
Data on hrHPV persistence in WLWH is scarce and
heterogeneous, therefore the aim of this study was to
assess the distribution of hrHPV genotypes, risk factors
of type-specific hrHPV persistence, cervical cytological
abnormalities and CIN in WLWH in Denmark.
Methods
Setting
In Denmark, the estimated HIV prevalence among
adults is 0.1% [21]. Medical care, including ART, is tax-
paid and provided free-of-charge [13]. HIV treatment is
restricted to nine specialized medical centers with out-
patient visits every 3–6 months [22]. Six of these centers
participated in this prospective, observational cohort
study of WLWH in Denmark [23] called Study on HIV,
cervical Abnormalities and infections in women in
Denmark (SHADE) [13, 23].
In the SHADE, WLWH were consecutively enrolled
from 1 February 2011 to 1 February 2012 and followed-
up after 6, 12 and 24 months. Inclusion criteria were
HIV-1 infection and ≥ 18 years of age. At each visit all
participants underwent a gynecological examination in-
cluding an HPV test and a cervical cytology sample. In
the present study, WLWH entered the analyses the day
they were diagnosed hrHPV positive. If applicable,
WLWH were censured at time of conization/hysterec-
tomy. Exclusion criteria were pregnancy at first visit,
prior hysterectomy, alcohol and/or drug abuse impeding
adherence to the protocol. Information on tobacco use,
age at sexual debut, lifetime sexual partners, prior con-
dyloma, HPV vaccination status, and contraceptive use
was obtained from a questionnaire (Additional file 1)
[13, 23]. The EpiData Entry program was used for
double manual data entry [24].
Registry data
Civil registration system (CRS)
The CRS is a national registry of all Danish residents
[25]. A 10-digit personal identification number (PIN) is
assigned to each individual at birth or immigration. This
PIN was used to link data from the SHADE cohort, the
Danish HIV Cohort Study (DHCS) and the The Danish
Pathology Data Bank (DPDB).
Danish HIV cohort study (DHCS)
The DHCS is a prospective, observational, nationwide,
multicenter cohort study of all PLWH seen at the
Danish HIV centers since 1 January 1995 and has been
described in detail elsewhere [22]. We retrieved HIV
demographics from the DHCS.
The Danish pathology data Bank (DPDB)
The DPDB contains nationwide records of all pathology
specimens analyzed in Denmark since 1997 [26]. Cy-
tology and histology samples were retrieved using the
Systemized Nomenclature of Medicine (SNOMED) code
of cervix uteri and uterus: T8x2*, T8x3*, T82* and T83*.
Cytology and HPV testing
Cervical samples were collected using the combi brush
(Rovers, Oss, The Netherlands) in SurePath liquid based
cytology media (BD Diagnostics, Durham, NC, US) and
analyzed at the Department of Pathology, Copenhagen
University Hospital, Hvidovre. The Bethesda 2001 sys-
tem was used to report the cytology results [27].
Samples were classified as normal, atypical cells of un-
determined significance (ASCUS), low-grade squamous
intraepithelial lesions (LSIL), or high-grade squamous
intraepithelial lesions (HSIL) (including atypical squa-
mous cells - cannot exclude HSIL (ASC-H), atypical
glandular cells and adenocarcinoma in situ), squamous
cell-and adenocarcinoma. Histology reports of CIN
grade 1 (CIN1), CIN grade 2 (CIN2), CIN grade 3
(CIN3) and CC were based on biopsies. Cytology and
histology results were presented as the worst cytology/
histology result diagnosed concurrent with or after a
positive hrHPV test.
Cervical samples for HPV testing were collected using
flocked swabs (UTM-RT viral transport media Flocked
Polyester Swabs, Copan Diagnostics, Inc., Murrieta, CA).
All samples were stored at room temperature and exam-
ined by the CLART HPV2 assay (Genomica, Madrid,
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Spain) at the Department of Pathology, Copenhagen
University Hospital, Hvidovre. PCR amplification of
genotype specific HPV L1 fragments from 35 individual
HPV genotypes was performed; of these 13 were hrHPV
genotypes: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68 [28].
Definition of type-specific persistence versus clearance
Type-specific persistence was defined as positivity of the
same hrHPV type in two separate cervical samples hav-
ing been taken at least 1 year and at most 2 years after
the date the patient was first hrHPV positive. Clearance
was defined as having one or more negative results after
a hrHPV positive sample [29]. WLWH with type-specific
persistence of one genotype and clearance of another
were reported as having persistent HPV infection.
Statistical analysis
Continuous variables were summarized as median and
interquartile ranges (IQR) and compared using the
Wilcoxon rank sum test. Categorical variables were re-
ported as counts and percentages and compared using
the chi-square test or Fisher’s exact test, where appropri-
ate. Univariate and multiple logistic regression analyses
were used to identify predictors of persistent hrHPV,
ASCUS or worse (≥ASCUS), LSIL or worse (≥LSIL), and
HSIL or worse (≥HSIL) expressed as odds ratios (OR)
and 95% confidence intervals (CI). We chose six candi-
date predictor variables a priori due to current know-
ledge on risk factors of HPV infection [13, 30, 31]; age
(18–34 vs. ≥ 35 years), race (White, Asian, and Black),
duration of ART (years on ART), AIDS prior to inclu-
sion, smoking status (never smoker vs. current smoker/
ex-smoker) and latest CD4 count when first hrHPV
positive (< 350 and ≥ 350 cells/μL). Predictors of
≥ASCUS, ≥LSIL, and ≥HSIL were estimated by includ-
ing the aforementioned variables and additionally
persistent hrHPV infection. Since duration of ART, prior
AIDS and the CD4 count are dependent covariates, two
models were used: 1) a model where all variables but the
latest CD4 count was included and 2) a model where
duration of ART and prior AIDS were replaced by latest
CD4. From the second model only, the OR of the CD4
count was presented.
In all analyses p-values < 0.05 (two-tailed) were consid-
ered significant. For category variables with more than
two outcome categories (df > 1), we controlled for re-
peated testing by estimating the combined p-value. We
excluded individuals with missing explanatory values
from the multiple regression analyses. The validity of the
model was tested using the Hosmer and Lemeshow
Goodness-of-Fit Test. SAS statistical software version
9.4 (SAS Institute Inc., Cary, NC, USA) was used for
data analysis.
Results
Overall, 334 WLWH were included in the overall
SHADE study, and of these, 252 (75.5%), 245 (73.4%)
and 234 (70.1%), respectively, participated at the subse-
quent visits at 6, 12 and 24months after inclusion
(Fig. 1). During follow-up, 96 WLWH (28.7%) presented
with at least one hrHPV-positive test through the course
of three visits. Of these, 25 WLWH (26.0%) had an
indeterminable course of HPV infection either if no fol-
low-up tests were performed or censored at time of con-
ization (none were hysterectomized). In total, 71
WLWH were included in this analysis (Fig. 1).
Of the 71 included WLWH, 31 (43.7%) had persistent
hrHPV infection (Fig. 1). Table 1 shows baseline charac-
teristics of WLWH with persistent and cleared hrHPV
infection. Median age was 42.5 (IQR 33.8–49.5) years.
The majority of WLWH (96.7 and 83.8%) were sexually
infected with HIV and were on ART with HIV-RNA <
40 copies/mL (80.8 and 72.7%). More WLWH in the
hrHPV persistence group had a CD4 count< 350 cells/
μL (40.7% vs. 15.2%, p = 0.03) (Table 1).
Multiple (≥2) hrHPV infections were present in 23 of
71 women at inclusion (32.4%). Predominant hrHPV ge-
notypes were HPV58 (n = 20; 28.1%), 52 (n = 14; 19.7%),
51 (n = 13; 18.3%) and 35 (n = 13; 18.3%). HrHPV geno-
types most likely to persist were HPV52, 33 and 31
(78.6, 42.9, and 40.0%) (Table 2). One woman was vacci-
nated against HPV (name of vaccine unknown) (Table 1)
and had persistent HPV35.
Predictor of HPV persistence was CD4 < 350 cells/μL
(adjusted OR 4.36 (95%CI: 1.18–16.04), Table 3). Pre-
dictor of concurrent cytology findings of ≥ASCUS and ≥
LSIL was short duration of ART (≥ASCUS: adjusted OR
0.85 (95%CI: 0.74–0.99), Table 4 and Additional file 2,
≥LSIL: adjusted OR 0.83 (95%CI: 0.71–0.97), Table 4
and Additional file 3). Despite low numbers, ≥HSIL was
predicted by prior AIDS (adjusted OR 8.55 (95%CI
1.21–60.28), Table 4 and Additional file 4). Due to a
limited number of events predictors of CIN were not
estimated. There was no significant difference between
the HPV persistence and the HPV clearance group and
their cytological and histological outcomes.
Discussion
In this prospective cohort study of well-treated, hrHPV-
positive WLWH in Denmark, more than 40% of the
hrHPV positive had persistent hrHPV infection, a third
had multiple hrHPV infections. HrHPV genotypes other
than HPV16 and 18 predominated. CD4 < 350 cells/μL
predicted genotype-specific hrHPV persistence. Cyto-
logical abnormalities were predicted by short duration of
ART and prior AIDS.
Some have challenged the idea of inclusion of concur-
rent HPV testing in WLWH, due to the high incidence
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of cervical hrHPV in WLWH > 30 years of age, which
may reduce the benefit of a combined HPV test and cer-
vical cytology for CC screening in this population [32].
Still, a better triage test for HPV-infected WLWH to
improve efficiency of cervical screening is of importance.
While HPV testing offers many advantages over liquid-
based cytology and is more sensitive in detection of
high-grade precancerous lesions [33, 34], cervical
cytology is more specific. However, in the WLWH popu-
lation with a high HPV prevalence, HPV screening can
lead to over-referral and adverse events associated with
overtreatment (6). In Denmark more than 10% of
WLWH have had a cone biopsy performed compared
with 4% of women in the general population and the
intervention was performed at earlier CIN stages [35].
Whether this reflects a more aggressive clinical practice
for WLWH than women without HIV is unknown.
The relationship between HIV infection, persistent
hrHPV and CC is not well understood [36]. It has been
suggested that a combination of increased susceptibility
to HPV infection, decreased ability to clear the infection
caused by impaired cell-mediated immunity, and reacti-
vation of latent HPV infection associated with immuno-
suppression could explain the both increased prevalence,
incidence and persistence of hrHPV among WLWH
[10]. A small study of 19 WLWH and 19 HIV-negative
women suggested that high regulatory T-cells and low
plasmacytoid dendritic cells levels might be associated
with hrHPV persistence in both groups [36].
In Denmark, CC is highly prevalent [37] and our
current findings on persistence is mirrored in a study in-
cluding 2874 women from the general Danish popula-
tion where hrHPV persistence was found in 31.4% of the
hrHPV positive women [29], with a follow-up of 1 to
4.5 years vs. 2 years in the present study.
In the present study persistent genotype specific
hrHPV infection was defined as hrHPV persistence last-
ing at least 1 year as done previously [29] and found in
43.7% of WLWH. Comparison of hrHPV persistence
rates with other studies is in general hampered by varia-
tions in HPV detection between used molecular HPV
tests [30] and in the definition of persistence [1, 38]. A
study in WLWH from Nigeria found a 6 months hrHPV
persistence rate of 15.9% using the SPF10-LiPA HPV
test, which is highly sensitive for detection of HPV geno-
types [14]. Likewise, the MACH-1 study, where the per-
sistence rate was 55.8%, defined persistence as being
positive in two samples more than 6months apart [32]
using the Hybrid Capture 2 (HC2) hybridization assay
and genotyping HC2 positive samples using HPV Line
Blot Assay. For both studies, the interval to define per-
sistence was short, and the used HPV testing strategy
Fig. 1 Flowchart of inclusion, follow-up and course of hrHPV infection. WLWH=Women living with HIV. SHADE = Study on HIV, cervical Abnormalities
and infections in women in Denmark. hrHPV = High-risk human papillomavirus
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Table 1 Characteristics of study participants with persistenta and clearedb high-risk (hr) human papillomavirus (HPV) infection during
the study period 2011–2014 (n = 71)
hrHPV persistence hrHPV clearance p-value
Number of individuals, n(%) 31 (43.7) 40 (56.3) –
HIV duration (years), median (IQR) 7.6 (3.5–17.3) 11.5 (6.2–16.6) 0.45
Age at inclusion (years), median (IQR), 46.6 (34.0–51.3) 39.6 (33.5–47.4) 0.18
Race, n(%)
White 13 (41.9) 20 (51.2) 0.29
Asian 4 (12.9) 1 (2.6)
Black 14 (45.2) 17 (43.6)
Other 0 (0) 1 (2.6)
(missing) (0) (1)
Place of HIV transmission, n(%)
Denmark 11 (36.7) 16 (42.1) 0.05
Europe + US 1 (3.3) 6 (15.8)
Africa 14 (46.7) 16 (42.1)
Asia 4 (13.3) 0 (0)
(missing) (1) (2)
Mode of transmission, n(%)
Heterosexual 29 (96.7) 31 (83.8) 0.32
IDU 1 (3.3) 4 (10.8)
Other 0 (0) 2 (5.4)
(missing) (1) (3)
ARTc at inclusion, n(%)
Yes 30 (96.8) 37 (92.5) 0.63
No 1 (3.2) 3 (7.5)
(missing) (0) (0)
ARTc duration (years), median (IQR) 5.4 (3.4–11.4) 8.1 (2.6–12.1) 0.66
On ARTc with HIV RNA < 40 copies/mL, n(%)
Yes 21 (80.8) 24 (72.7) 0.47
No 5 (19.2) 9 (27.3)
(missing) (5) (7)
CD4 count at inclusion (cells/μL), n(%)
< 350 11 (40.7) 5 (15.2) 0.026
≥ 350 16 (59.3) 28 (84.8)
(missing) (4) (7)
AIDS prior to inclusion, n(%)
Yes 10 (32.3) 6 (15.4) 0.10
No 21 (67.7) 33 (84.6)
(missing) (0) (1)
HPV vaccination prior to inclusion, n(%)
No 29 (96.7) 40 (100.0) 0.43
Yes (4-valent HPV vaccine) 0 (0) 0 (0)
Yes (2-valent HPV vaccine) 0 (0) 0 (0)
Yes (name of vaccine unknown) 1 (3.3) 0 (0)
(missing) (1) (0)
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designed to pick up HPV infections with a high sensitiv-
ity. In contrast, a Brazilian study of HPV infected, preg-
nant WLWH with a test interval of 18 months found
hrHPV persistence in 18 of 90 women (20.0%) if the
study was re-calculated to the 13 genotypes considered
hrHPV in the present study [30], but the pregnant status
of the enrolled women changes the premise as previous
studies have found HPV clearance to be more likely
occur late in pregnancy or postpartum, than in the first
two trimesters [30, 39]. Finally, an Italian study found
27/35 (77.1) WLWH to have hrHPV persistence at the
end of 14 months follow-up [40].
Evidence is conflicting as to whether any hrHPV geno-
type persists longer than others [1]. Yet, it is well estab-
lished that individual hrHPV genotypes differ in their
relative carcinogenic potential [1–5]. Compared to HIV-
negative women, as in the large Danish study [29], our
and other previous reports show that WLWH have a
higher proportion of multiple HPV infections [32, 41]
with HPV genotypes other than HPV16 and 18 prevail-
ing [13–16, 41]. In the SHADE study, the predominant
hrHPV genotypes were HPV58, 52, 51, and 35 [13]. A
worldwide review of almost 20,000 WLWH found that
in the African region HPV16, 18 and 45 positivity in-
creased consistently with severity of cervical diagnosis
compared to normal cytological samples as well as in
confirmed CC [4]. Among European WLWH only
HPV33 positivity increased by severity [4]. The finding
of non-HPV16 genotypes in high-grade CIN and CC in
WLWH is proposed to be explained by the lower
Table 1 Characteristics of study participants with persistenta and clearedb high-risk (hr) human papillomavirus (HPV) infection during
the study period 2011–2014 (n = 71) (Continued)
hrHPV persistence hrHPV clearance p-value
Age at sexual debut, n(%)
< 16 10 (32.3) 14 (35.0) 0.81
≥ 16 21 (67.7) 26 (65.0)
(missing) (0) (0)
Lifetime sexual partners, n(%)
< 5 7 (22.6) 5 (12.5) 0.59
5–14 14 (45.2) 23 (57.5)
15–25 3 (9.7) 5 (12.5)
> 25 7 (22.6) 7 (17.5)
(missing) (0) (0)
aPersistent = Type-specific persistence was defined as positivity of the same hrHPV type in two separate cervical samples having been taken at least 1 year and at
most 2 years after the date the patient was first hrHPV positive, bCleared = having one or more negative results after an hrHPV positive sample, cART =
antiretroviral therapy
Table 2 Distribution of persistenta and clearedb high-risk (hr) human papillomavirus (HPV) infections in 71 included WLWH
HrHPV infections, n(% of total number of WLWH) (n = 112) HrHPV persistence, n(%) HrHPV clearance, n(%)
hrHPV16 12 (10.7) 4 (33.3) 8 (66.7)
hrHPV18 5 (4.4) 0 (0) 5 (100.0)
hrHPV31 10 (8.9) 4 (40.0) 6 (60.0)
hrHPV33 7 (6.3) 3 (42.9) 4 (57.1)
hrHPV35 13 (11.6) 5 (38.5) 8 (61.5)
hrHPV39 4 (3.6) 0 (0) 4 (100.0)
hrHPV45 3 (2.7) 1 (33.3) 2 (66.7)
hrHPV51 13 (11.6) 4 (30.8) 9 (69.2)
hrHPV52 14 (12.5) 11 (78.6) 3 (21.4)
hrHPV56 5 (4.4) 1 (20.0) 4 (80.0)
hrHPV58 20 (17.9) 5 (25.0) 15 (75.0)
hrHPV59 0 (0) 0 (0) 0 (0)
hrHPV68 6 (5.4) 0 (0) 6 (100.0)
WLWH = women living with HIV
aPersistent = Type-specific persistence was defined as positivity of the same hrHPV type in two separate cervical samples having been taken at least 1 year and at
most 2 years after the date the patient was first hrHPV positive, bCleared = having one or more negative results after an hrHPV positive sample
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influence of immunodeficiency on HPV16 than on other
hrHPV genotypes, due to the better intrinsic ability of
HPV16 to evade immunological control even in im-
munocompetent individuals [42].
In an update on the natural history of HPV, Moscicki
et al. [1] stated that the strongest factor resulting in per-
sistent infection is likely the lack of an adequate immune
response. This statement is supported by the results of
the present and other cohorts [12, 30, 43], where current
low CD4 count predicted hrHPV persistence. The im-
pact of ART on hrHPV and HPV-related disease is still
controversial [10, 11, 31]. Median ART duration in the
present study was > 5 years, but no association with ART
duration and hrHPV persistence was found. Since this
study was performed before the publication of the
START study advocating for early ART initiation [44],
ART initiation was deferred until the occurrence of the
following; HIV-related disease, AIDS defining illness,
pregnancy and CD4 count< 350 cells/μl [45]. Therefore,
WLWH initiated ART at later HIV stages than in recent
studies, which is known to impact morbidity and mortal-
ity [11]. A study by Konopnicki et al. [31] suggests that
> 3 years of undetectable HIV-RNA and > 1.5 years of
CD4 counts of > 500 cells/μL are needed to obtain
hrHPV clearance and demonstrated a decreased risk of
persistent hrHPV infection in WLWH with sustained
immunological reconstitution and long-lasting HIV
suppression [31]. Other studies finding no effect of ART
on HPV were mostly performed in the early ART era,
and might therefore be affected by factors such as higher
toxicity in older ART drugs, resulting in treatment delay
and/or poor adherence [11]. The contradictory results
regarding ART and HPV persistence might be owing to
complex interactions between HPV, ART and duration
Table 3 Unadjusted and adjusted odds ratios for predictors of persistent high-risk (hr) human papillomavirus (HPV) infection (n = 71)
Predictors of persistence HrHPV Persistence
(n = 31)
HrHPV Clearance
(n = 40)
Unadjusted
odds ratios
p-value Adjusted
odds ratiosa, b
p-value
Age when first hrHPV positive, n(%)
≥ 35 years 22 (44.9) 27 (55.1) 1.00 – 1.00 –
18–34 years 9 (40.9) 13 (59.1) 0.85 (0.31–2.36) 0.75 0.52 (0.13–2.07) 0.35
(missing) (0) (0)
Race, n(%)
White 13 (39.4) 20 (60.6) 1.00 – 1.00 –
Asian 4 (80.0) 1 (20.0) 6.15 (0.62–61.37) 0.12 7.38 (0.68–80.17) 0.10
Black 14 (45.2) 17 (54.8) 1.27 (0.47–3.42) 0.64 1.71 (0.52–5.64) 0.38
(missing) (0) (2)
Combined p-value 0.30 0.22
ART duration, (years)
Median (IQR) 5.4 (3.3–11.4) 8.1 (2.6–12.1) 0.97 (0.88–1.07) 0.52 0.91 (0.80–1.04) 0.17
(missing) (1) (3)
AIDS prior to inclusion, n(%)
No 21 (38.9) 33 (61.1) 1.00 – 1.00 –
Yes 10 (62.5) 6 (37.5) 2.62 (0.83–8.28) 0.10 3.77 (0.99–14.38)
(missing) (0) (1) 0.05
Smoking status, n(%)
Never smoker 17 (43.6) 22 (56.4) 1.00 – 1.00
Current smoker/ Ex-smoker 14 (43.8) 18 (56.2) 1.01 (0.39–2.58) 0.99 1.13 (0.35–3.68) 0.84
(missing) (0) (0)
CD4 count when first hrHPV
positive (cells/μL), n(%)
≥ 350 16 (36.4) 28 (63.6) 1.00 – 1.00
350 11 (68.8) 5 (31.2) 3.85 (1.13–13.07) 0.03 4.36 (1.18–16.04) 0.03
(missing) (4) (7)
ART = combined antiretroviral therapy
aThe validity of the model was tested using the Hosmer and Lemeshow Goodness-of-Fit Test, bDuration of ART, AIDS prior to inclusion and CD4 count are
dependent covariates and where calculated using two models: A model where all variables, but CD4 at inclusion were included and a model where duration of
ART and AIDS prior to inclusion were replaced by CD4. We only present the OR of the CD4 count from the second model
Thorsteinsson et al. BMC Infectious Diseases          (2019) 19:740 Page 7 of 10
and level of immunodeficiency/immune reconstitution
[31, 46]. One study found that higher HPV16 viral loads
were predictive of persistent HPV16 infection [47].
Our analyses of predictors of cytological abnormalities
should be interpreted with caution due to the sample
size. Nevertheless, ≥ASCUS and ≥ LSIL were predicted
by short duration of ART, while ≥HSIL was predicted by
prior AIDS, serving as a proxy of prior severe immuno-
deficiency. This difference in predictor may reflect that
HPV infection is thought to progress via two pathways
[17]; transient low-grade lesions that do not progress to
high-grade CIN reflecting active HPV replication, and
high-grade (precancerous) lesions mirroring HPV-in-
duced transformation [17].
Limitations and strengths
Strengths include the well-characterized cohort and the
use of nationwide registries. Furthermore, cytological
abnormalities were followed-up by histopathological
confirmation. Finally, HPV and cytology analyses were
performed routinely in a tested, high-throughput, qual-
ity-controlled and quality-assured laboratory. The study
has limitations including the lack of a control group, the
fact that some patients did not participate in all planned
visits, the relatively small sample size and accordingly
low rate of CIN, precluding us from performing detailed
analyses on high grade CIN. Finally, detection of HPV at
two-time points could reflect clearance and subsequent
reinfection and not real viral persistence [48], yet this
limitation can only be overcome by massive, short inter-
val testing outside the scope of most studies.
Conclusion
Studies on hrHPV persistence in WLWH are diverse
and scarce. This prospective cohort study of well-treated
WLWH in Denmark found a high rate of persistent
hrHPV infections with predominantly non-16/18 hrHPV
genotypes. Low CD4 count predicted hrHPV persistence,
while prior AIDS predicted ≥HSIL, which supports
continued focus on previously and currently immuno-
compromised WLWH with respect to screening for
HPV-related cancers.
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kb)
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